A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques.
G. Baisa, D. Rancour, K. Mansfield, M. Burns, L. Martin, D. Cunha, J. Fischer, F. Muecksch, T. Hatziioannou, P. Bieniasz, F. Schomburg, K. Luke
This study evaluates a recombinant SARS-CoV-2 vaccine in macaques, showing that antigens from the RBD elicit high-titer neutralizing antibodies lasting over 20 weeks.
bioRxiv · Dec 20, 2020 · PreprintImmunology